|Articles|October 12, 2020
Assessing Multiple Critical Quality Attributes of Monoclonal Antibody and Comparability Assessments
Author(s)Agilent Technologies
Discover how LC/MS peptide mapping can be used to characterize and quantify different monoclonal antibody (mAb) critical quality attributes (CQAs).
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
How Biopharma Navigates the 2026 Economic Shift
2
FDA October 2025 Draft Guidance Sparks Industry Biosimilars Buzz
3
Adenovirus Vectors, Cyclodextrins and the Patient Experience: A Deep Dive
4
EC’s High-Dose Aflibercept Approval Highlights Durable Anti-VEGF Retinal Therapy
5